Eye movement and visual attention in people with thyroid-associated eye disease
Official title: Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmopathy
Run by Shanghai Changzheng Hospital · NCT07381413 · Data updated 2026-11-12
This project uses non-invasive eye tracking to test whether people with thyroid-associated ophthalmopathy track moving objects and scan faces differently than healthy volunteers.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Shanghai Changzheng Hospital Academic / other |
| Locations | 1 site (Shanghai) |
| Status | Recruiting |
| Started | January 31, 2026 |
| Main results expected | May 2029 |
| Study ends | May 2029 |
| Registry record updated | February 6, 2026 |
| Trial ID | NCT07381413 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18–70 with adequate corrected vision who have TAO or are healthy volunteers, can give informed consent, and can follow on-screen instructions.
✕Probably not a fit
People with severe visual impairment, neurological or psychiatric disorders, prior eye muscle surgery, or recent use of sedating medications are unlikely to benefit or be eligible.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational project will enroll about 100 participants, including people with thyroid-associated ophthalmopathy (TAO) and healthy volunteers. Participants will sit in front of a screen while non-invasive eye-tracking equipment records gaze patterns as they follow moving targets and view faces. Investigators will measure eye stability, tracking accuracy, and how participants scan facial features to quantify physical and social-visual impacts of TAO. The goal is to produce objective data that could inform future monitoring and treatment strategies.
Why it matters
Potential benefit: If successful, the findings could provide objective measures of eye movement and social-visual changes that help clinicians track disease progression and personalize treatments.
How similar studies have gone: Eye-tracking has been used successfully to characterize gaze and eye-movement patterns in other ocular and neurologic conditions, but its application specifically to TAO is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged between 18 and 70 years, inclusive. * Willing and able to provide written informed consent. * Best-corrected visual acuity (BCVA) ≥ 1.0 in both eyes, with no history of ocular diseases or thyroid disorders. Exclusion Criteria: * Non-TAO Ocular Motility Disorders: History of conditions like myasthenia gravis, cranial nerve palsy, or congenital strabismus. * Neurological Diseases: Disorders affecting oculomotor control (e.g., Parkinson's, MS, stroke, or brain tumors). * Significant Visual Impairment: BCVA \< 0.5 due to media opacities or retinopathy, preventing clear visualization of stimuli. * Prior Ocular Surgery: History of surgeries affecting extraocular muscle mechanics (e.g., strabismus surgery, scleral buckling). * Psychiatric or Cognitive Disorders: Inability to follow instructions or conditions affecting eye movements (e.g., schizophrenia). * Medication Interference: Use of drugs affecting reaction time (e.g., sedatives) within 48 hours of testing.
Where it's running
-
Changzheng Hospital
Shanghai, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-based MRI and ultrasound for thyroid-related eye disease
This study tests an AI model using orbital MRI and eye ultrasound to help diagnose activity and severity of thyroid-associated ophthalmopathy and predict its course in adults.
-
Timing of AI Help in Chest X-Rays: Does When AI Becomes Visible Change How Clinicians Read Images?
Doctors test chest X-ray interpretation with AI information shown either before or after they start reviewing the image to see how timing affects their search patterns and decisions.
-
IBI311 for inactive thyroid‑related eye disease (TAO)
This trial tests whether IBI311, an anti–IGF‑1R antibody, can help people with inactive moderate-to-severe thyroid‑associated ophthalmopathy who still have symptoms or need further surgery.
-
Sequential hormone therapy followed by tetuzumab for moderate-to-severe active thyroid eye disease after steroid treatment
This trial will test whether adding tetuzumab after prior steroid treatment helps people with moderate-to-severe active thyroid eye disease.
-
Sequential glucocorticoid therapy followed by IBI311 for active moderate-to-severe thyroid eye disease
This trial tests whether giving standard glucocorticoids followed by the anti-IGF-1R antibody IBI311 helps adults with active moderate-to-severe thyroid-associated ophthalmopathy (TAO).
-
Hand gestures to support expression for autistic and language‑impaired people in rural areas
This research tests whether gestures adapted from American Sign Language help people with autism, developmental language disorders, or related conditions in rural communities understand and communicate words better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.